Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Preparation method and application of CIK (Cytokine-induced Killer) modified by anti-human CD19 chimeric antigen receptor

A chimeric antigen receptor, -CD3 technology, applied in genetically modified cells, botany equipment and methods, biochemical equipment and methods, etc. Normal tissue damage and other problems, to achieve the effect of preventing recurrence, improving immunity, and enhancing cell activity

Active Publication Date: 2017-03-29
SHANDONG XINRUI BIOTECH CO LTD
View PDF3 Cites 12 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although surgical resection can remove tumor lesions in some advanced patients, the effect on metastatic lesions is not good, and radiotherapy and chemotherapy can also cause damage to normal tissues in addition to diseased tissues, causing great harm to patients. death rate remains high

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Preparation method and application of CIK (Cytokine-induced Killer) modified by anti-human CD19 chimeric antigen receptor
  • Preparation method and application of CIK (Cytokine-induced Killer) modified by anti-human CD19 chimeric antigen receptor
  • Preparation method and application of CIK (Cytokine-induced Killer) modified by anti-human CD19 chimeric antigen receptor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1: Inserting the fusion gene fragment scFv(CD19)-CD8-(4-1BB)-CD3ζ into the lentiviral expression vector pLent-C-GFP

[0031] The fusion gene fragment scFv(CD19)-CD8-(4-1BB)-CD3ζ and the lentiviral expression vector pLent-C-GFP (purchased from Vigene) were double-digested with restriction endonucleases KpnⅠ and AsiSI, and the restriction enzyme digestion system See instructions. After the digested products were separated by agarose gel electrophoresis, DNA fragments were recovered using an agarose gel DNA fragment kit (purchased from Omega). The recovered fusion gene fragment was ligated with the linear vector by T4 ligase (purchased from TaKaRa Company) at 16° C. for 8 hours. Transfer the ligation product into E.coli Top10, pick a single clone after culturing at 37°C for 10 hours, screen the single clone inserting the fusion fragment by PCR, and extract the plasmid with a plasmid extraction kit (purchased from Omega) after culturing at 37°C for 12 hours , see ...

Embodiment 2

[0032] Example 2: Preparation of cytokine-induced killer cells modified by chimeric antigen receptor scFv(CD19)-CD8-(4-1BB)-CD3ζ

[0033] (1) Packaging preparation of lentivirus

[0034] Anti-CD19CAR opinion Figure 9 ;

[0035] The sequence of each module of Anti-CD19:

[0036] 1) CAR guide sequence (Leader)

[0037] 2) Humanized anti-human B-lymphoma CD19 single-chain antibody (VL-Linker-VH)

[0038] 3) CD8Hinge area (CD8Hinge)

[0039] 4) Transmembrane region of CD8 (CD8Tm)

[0040] 5) Intracellular domain of 4-1BB (4-1BB lc)

[0041] 6) Intracellular domain of CD3ζ (CD3lc)

[0042] (2) Preparation of cytokine-induced killer cells (CIK)

[0043] Take 50ml of the patient's autologous peripheral blood, and use TBD sample density separation medium (purchased from Tianjin Haoyanghuake Biology Co., Ltd.) to centrifuge at 900g for 25 minutes to separate peripheral blood mononuclear cells. After inducing culture for 24 hours with a culture medium (purchased from CORNING C...

Embodiment 3

[0053] Example 3: Anti-tumor effect of chimeric antigen receptor scFv(CD19)-CD8-(4-1BB)-CD3ζ modified CIK

[0054] (1) Related work before treatment:

[0055] Before the patient is treated with chimeric antigen receptor-modified T cells, it is necessary to confirm whether the patient's tumor antigen expresses the tumor antigen targeted by the chimeric antigen receptor-modified T cells.

[0056] Before receiving chimeric antigen receptor T cell therapy, patients must undergo a general physical examination, especially heart, lung, liver, kidney function and blood tests, to ensure the safety of the patient's treatment. The specific examination is as follows:

[0057] 1: Cardiac function test:

[0058] Before the treatment, the heart function of the patient is graded. If the heart function of the patient is grade 3 or above, the patient is not suitable for this treatment.

[0059] 2: Pulmonary function test:

[0060] Pulmonary function tests usually include pulmonary ventilatio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a preparation method and application of a CIK (Cytokine-induced Killer) modified by an anti-human CD19 chimeric antigen receptor. The preparation method comprises the steps of coding a fusion gene segment of the chimeric antigen receptor scFv (CD19)-CD8-(4-1BB)-CD3 zeta; inserting the fusion gene segment into a lentiviral expression vector; packaging into a lentivirus carried with a scFv (CD19)-CD8-(4-1BB)-CD3 zeta coding gene; and infecting the CIK induced by autologous lymphocytes of a patient on the lentivirus carried with the scFv (CD19)-CD8-(4-1BB)-CD3 zeta coding gene. The CIK modified by the chimeric antigen receptor scFv (CD19)-CD8-(4-1BB)-CD3 zeta can be applied in treatment of B cell lymphoma leukemia.

Description

technical field [0001] The invention belongs to the technical field of biology and new medicine, and discloses a preparation method and application of CIK modified by human anti-CD19 chimeric antigen receptor. Background technique [0002] The incidence of tumors is increasing year by year, and malignant tumors have seriously endangered human health. At present, tumor treatment methods have not yet made substantial progress, and current tumor treatment methods still remain in the traditional methods of surgical resection, chemotherapy and radiotherapy. Although surgical resection can remove tumor lesions in some advanced patients, the effect on metastatic lesions is not good, and radiotherapy and chemotherapy can also cause damage to normal tissues in addition to diseased tissues, causing great harm to patients. The death rate remains high. Therefore, people are trying to find a more secure and effective treatment strategy. Among them, tumor immunotherapy based on identifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N15/867C12N5/10A61K35/17A61P35/00
CPCA61K35/17C12N5/0646C12N15/86C12N2510/00C12N2740/14043C12N2800/107
Inventor 刘明录万磊李言志冯健海金海峰强邦明张传鹏
Owner SHANDONG XINRUI BIOTECH CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com